Michael Petusky

Stock Analyst at Barrington Research

(2.30)
# 2,667
Out of 5,146 analysts
226
Total ratings
42.16%
Success rate
-1.89%
Average return

Stocks Rated by Michael Petusky

Henry Schein
Feb 25, 2026
Maintains: Outperform
Price Target: $79$97
Current: $81.91
Upside: +18.42%
U.S. Physical Therapy
Feb 20, 2026
Maintains: Outperform
Price Target: $103
Current: $81.80
Upside: +25.92%
LeMaitre Vascular
Feb 20, 2026
Maintains: Outperform
Price Target: $95
Current: $91.21
Upside: +4.16%
Orthofix Medical
Feb 17, 2026
Maintains: Outperform
Price Target: $18
Current: $13.05
Upside: +37.93%
Bioventus
Feb 9, 2026
Initiates: Outperform
Price Target: $13
Current: $8.74
Upside: +48.74%
Haemonetics
Feb 6, 2026
Maintains: Outperform
Price Target: $93$94
Current: $62.46
Upside: +50.50%
Option Care Health
Jan 16, 2026
Maintains: Outperform
Price Target: $38$42
Current: $33.51
Upside: +25.34%
Anika Therapeutics
Jan 9, 2026
Maintains: Outperform
Price Target: $16
Current: $10.96
Upside: +46.05%
VerifyMe
Jan 6, 2026
Maintains: Outperform
Price Target: $1$1.5
Current: $0.99
Upside: +51.81%
DENTSPLY SIRONA
Jan 5, 2026
Maintains: Outperform
Price Target: $14
Current: $12.80
Upside: +9.38%
Maintains: Outperform
Price Target: $106
Current: $79.29
Upside: +33.69%
Maintains: Outperform
Price Target: $2.25
Current: $1.18
Upside: +90.68%
Downgrades: Market Perform
Price Target: n/a
Current: $7.31
Upside: -